Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Non-Current Debt (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Non-Current Debt for 4 consecutive years, with $209.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Debt rose 3.81% to $209.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $209.1 million, a 3.81% increase, with the full-year FY2025 number at $209.1 million, up 3.81% from a year prior.
  • Non-Current Debt was $209.1 million for Q4 2025 at Phathom Pharmaceuticals, up from $207.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $209.1 million in Q4 2025 to a low of $91.0 million in Q1 2022.
  • A 4-year average of $145.6 million and a median of $143.4 million in 2023 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: skyrocketed 78.34% in 2024, then grew 3.81% in 2025.
  • Phathom Pharmaceuticals' Non-Current Debt stood at $95.3 million in 2022, then skyrocketed by 44.69% to $137.8 million in 2023, then soared by 46.12% to $201.4 million in 2024, then rose by 3.81% to $209.1 million in 2025.
  • Per Business Quant, the three most recent readings for PHAT's Non-Current Debt are $209.1 million (Q4 2025), $207.1 million (Q3 2025), and $205.1 million (Q2 2025).